−2.20USD
−35.14 MUSD
5.00 KUSD
15.36 M
About Alaunos Therapeutics, Inc.
Sector
Industry
CEO
Dale Curtis Hogue
Website
Headquarters
Houston
Employees (FY)
1
Founded
2003
FIGI
BBG000FWCC57
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of TCRT is 1.18 USD — it has decreased by 1.67% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Alaunos Therapeutics, Inc. stocks are traded under the ticker TCRT.
Alaunos Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
TCRT stock is 11.97% volatile and has beta coefficient of 1.82. Check out the list of the most volatile stocks — is Alaunos Therapeutics, Inc. there?
TCRT earnings for the last quarter are −0.60 USD per share, whereas the estimation was −0.53 USD resulting in a −14.29% surprise. The estimated earnings for the next quarter are −0.45 USD per share. See more details about Alaunos Therapeutics, Inc. earnings.
Yes, you can track Alaunos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
TCRT stock has fallen by 10.61% compared to the previous week, the month change is a 34.81% fall, over the last year Alaunos Therapeutics, Inc. has showed a 84.28% decrease.
TCRT net income for the last quarter is −7.84 M USD, while the quarter before that showed −8.48 M USD of net income which accounts for 7.47% change. Track more Alaunos Therapeutics, Inc. financial stats to get the full picture.
Today Alaunos Therapeutics, Inc. has the market capitalization of 19.22 M, it has decreased by 15.50% over the last week.
No, TCRT doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TCRT shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alaunos Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 1.00 employees. See our rating of the largest employees — is Alaunos Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alaunos Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alaunos Therapeutics, Inc. stock shows the sell signal. See more of Alaunos Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Alaunos Therapeutics, Inc. EBITDA is −24.96 M USD, and current EBITDA margin is −523.56 K%. See more stats in Alaunos Therapeutics, Inc. financial statements.